Scroll for more

news

featured

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Recent

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Apr 26, 2017 articles

9 Computational Drug Discovery Startups Using AI

Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Apr 13, 2017 articles

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Apr 11, 2017 announcements

BenevolentAI agrees partnership with medical research charity MRC technology

London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.

Mar 20, 2017 articles

BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio

An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI

Mar 16, 2017 articles

Advances in AI and ML are reshaping healthcare

Read more about TechCrunch's article on startups using artificial intelligence and machine learning to improve healthcare.

Mar 14, 2017 articles

Turning rare diseases into efficient targets with AI

The article discusses the rapid transformation of medical research lead by data, artificial intelligence and supercomputers

Feb 21, 2017 articles

Bold claims for AI are hard to compute for economists

The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.

Jan 11, 2017 announcements

British technology firm appointed to the global ‘AI 100’ for advancing artificial intelligence in drug discovery

Revealed at the 2017 CB Insights Innovation Summit, Santa Barbara, California

Jan 6, 2017 articles

BenevolentAI gets The Economist thinking on biology and AI

We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method.